Beken Bio develops minimally invasive liquid biopsies that will help diagnose cancer at its earliest stage using our patent-pending 3D REVEAL™ engine to open the door for effective treatment when time is most crucial.
2 in 5 people will be diagnosed with cancer at some point in their life, and by 2040, global cancer deaths are projected to exceed 16.2 million a year.
We envision a world where this estimation isn’t reality, and the question of late-stage diagnosis is answered with a solution.
Beken Bio’s 3D REVEAL™ Engine identifies novel cancer biomarkers that show up in the blood before symptoms are present, empowering doctors with the earliest form of detection possible, and potentially reducing cancer related deaths through clinically qualified diagnostic tests.
39.5%
of people will be diagnosed with cancer at some point in their lives.
Those who discover it at
an early stage are
90%
more likely to survive.
38% of people will be diagnosed with cancer at some point in their lives.
Those who discover it at an early stage are 90% more likely to survive.
Beken Bio is pioneering its proprietary 3D Recapitulation of Extracellular Vesicles bearing Enriched Antigens for Liquid biopsy, also known as our 3D REVEAL™ engine.
By tricking cancer cells into producing EVs as if they are still in the tumor, we’re able to pinpoint the exact molecular signature exclusive to EVs of a given cancer type, unlocking the cell signaling code to early detection.
Tricking cancer cells into producing enriched EVs in a proprietary 3D matrix.
Identifying EV protein signatures for specific cancer types through proprietary data analysis A.I.
Empower doctors and patients with accurate tests to enable effective treatment.
A routine blood draw could be all it takes to detect pre-symptomatic cancer.